Longitudinal comparison of outcomes in patients with smoking-related asthma-COPD overlap and in non-smoking asthmatics with incomplete reversibility of airway obstruction

Louis-Philippe Boulet, Marie-Eve Boulay, Joanne Milot, Johane Lepage, Lara Bilodeau, François Maltais

Research Center, Quebec Heart and Lung Institute-Laval University, Quebec, QC, Canada

Background: There is a need to characterize the impact of the smoking status on the clinical course of asthmatics with incomplete reversibility of airway obstruction (IRAO).
Objective: To compare longitudinal health care use, symptom control, and medication needs between smoking and non-smoking asthmatics with IRAO.
Materials and methods: This was a 12-month follow-up of a cross-sectional study comparing asthmatics with IRAO according to their tobacco exposure. One group had a tobacco exposure ≥20 pack-years and was considered to have asthma-COPD overlap (ACO) and the second with a past tobacco exposure 
Results: A total of 111 patients completed all follow-up telephone calls: 71 ACO and 40 NS-IRAO. The number of exacerbations per patient over the 12-month follow-up was similar in both groups. However, ACO reported worse symptom control throughout the follow-up as compared to NS-IRAO, although no significant variations within a group were observed over the study period.
Conclusion: Although asthma control scores were poorer in ACO patients over 1 year compared to NS-IRAO, exacerbation rate was similar and low in both groups of asthmatics. These observations suggest that poorer asthma control in ACO was not driven by the number of exacerbations but may reflect the influence of chronic airway changes related to the COPD component.

Download Article [PDF]

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: FDA to Review BLA for Oral Immunotherapy AR101 for Peanut Allergy - Pulmonology Advisor… https://t.co/JSl0Dhdy2k
Interasma RT @Aller_MD: “VIDEO: #Dupilumab or cyclosporine for treating atopic dermatitis?” https://t.co/sIseou6JYq https://t.co/4h02wi3UUa
Interasma RT @Aller_MD: “More than one in five infants with a bronchiolitis hospital admission will have a subsequent respiratory-related hospital ad…
Interasma RT @Aller_MD: “FDA to Review BLA for Oral Immunotherapy AR101 for Peanut #Allergyhttps://t.co/4UDldOOtRd https://t.co/HNeJTDeR9s
Interasma RT @Aller_MD: 10 startups tackling the problem of high prescription drug costs. Managing payments, connecting consumers to reimbursement op…

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA